Fundraising Fox
EvolveImmune Therapeutics
Branford, US · Founded 2020 · 56 employees on LinkedIn · 5 known investors
Find your way into EvolveImmune Therapeutics
Sign up to see every warm intro you have to EvolveImmune Therapeutics
- Paths you didn't know you had: your email and LinkedIn already hold routes to the EvolveImmune Therapeutics team. We find them for you
- 2nd- and 3rd-degree connections: the friend-of-a-friend routes that take hours to manually find through your inbox or LinkedIn
- Answers now, not in days: momentum is everything in a raise. Skip asking around whether someone knows someone
Days of research, done the moment you sign in, with every route ranked by how warm it is.
EvolveImmune develops immunotherapy treatments for cancer patients. The company focuses on discovering and developing novel biotherapeutics in immuno-oncology and related immune-mediated diseases.
Founders & leadership
EvolveImmune Therapeutics was founded in 2020 by Stephen Bloch.
Board
Investors · 5
How we know: the company's own site · funding news · press coverage · Not right? Tell us
How we know: the company's own site · Not right? Tell us
How we know: Elm Street Ventures's portfolio page · Not right? Tell us
How we know: Pfizer Venture Investments's portfolio page · funding news · press coverage · the VCSheet dataset · Not right? Tell us
How we know: board seat on SEC Form D · funding news · press coverage · Not right? Tell us
Reported raises · per SEC filings
Form D private placements$85.8M disclosed across 4 rounds · 2020–2024
▶$20MraisedNov 2024 · 1 investors · BiotechnologyRule 506(b)
- Donmienne LeungDirector
- Ian TaylorDirector
- Derek YoonDirector
- Stephen BlochExecutive Officer, Director
- Jasmina MarjanovicDirector
- Denis PatrickDirector
- Offering amount
- $20M
- Amount sold
- $20M
- First sale
- Oct 2024
- Incorporated
- Limited Liability Company, Delaware, 2019
- Federal exemptions
- 06b
▶$37.4MraisedNov 2023 · 9 investors · BiotechnologyRule 506(b)
- Denis PatrickDirector
- Derek YoonDirector
- Ian TaylorDirector
- Stephen BlochExecutive Officer, Director
- Alessandra Di BaccoDirector
- Offering amount
- $57.4M
- Amount sold
- $37.4M
- First sale
- Nov 2023
- Incorporated
- Limited Liability Company, Delaware, 2019
- Federal exemptions
- 06b
▶$10.8MraisedJan 2023 · 8 investors · BiotechnologyRule 506(b)
- Denis PatrickDirector
- Derek YoonDirector
- Ian TaylorDirector
- Stephen BlochExecutive Officer, Director
- Alessandra Di BaccoDirector
- Offering amount
- $26M
- Amount sold
- $10.8M
- First sale
- Jan 2023
- Incorporated
- Limited Liability Company, Delaware, 2019
- Federal exemptions
- 06b
▶$17.5MraisedJan 2020 · 8 investors · BiotechnologyRule 506(b)
- Stephen BlochExecutive Officer
- Alessandra Di BaccoDirector
- Hugo BeekmanDirector
- Denis PatrickDirector
- Offering amount
- $35.1M
- Amount sold
- $17.5M
- First sale
- Jan 2020
- Incorporated
- Limited Liability Company, Delaware, 2019
- Federal exemptions
- 06b
Source: SEC EDGAR Form D. Amounts as filed; amended filings shown once at their latest values.
Founder mafia
3 people who came through EvolveImmune Therapeutics went on to found or lead other companies.
Frequently asked questions
- What does EvolveImmune Therapeutics do?
- EvolveImmune develops immunotherapy treatments for cancer patients. The company focuses on discovering and developing novel biotherapeutics in immuno-oncology and related immune-mediated diseases.
- Who founded EvolveImmune Therapeutics?
- EvolveImmune Therapeutics was founded by Stephen Bloch in 2020.
- Who are EvolveImmune Therapeutics's investors?
- EvolveImmune Therapeutics's investors include Solasta Ventures, Pfizer Ventures, Elm Street Ventures, Pfizer Venture Investments, Takeda Ventures.
- How much funding has EvolveImmune Therapeutics raised?
- EvolveImmune Therapeutics has disclosed $85.8M raised across 4 rounds.
- Where is EvolveImmune Therapeutics headquartered?
- EvolveImmune Therapeutics is headquartered in Branford, US.